The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
NORTH CHICAGO, Ill., May 27, 2022 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced The Lancet published results from three pivotal Phase…